Possible use of psilocybin in psychiatric care, including COVID-19 sequelae
DOI:
https://doi.org/10.33448/rsd-v10i11.19259Keywords:
Psilocybin; Psychiatry; Depression; Anxiety; Palliative care; Hallucinogens.Abstract
This paper discuss psilocybin’s effect on the human organism and its therapeutic potential as a main or adjuvant medication for certain psychiatric diseases, more specifically, depression and anxiety, such as found in palliative care patients which are facing the end-of-life process, but also on those patients in which the conventional treatment was not effective. Recent studies also present the possibility of the use of psilocybin in the treatment of long-term psychiatric consequences of COVID. The available literature indicates that psilocybin promotes heightening of quality of life, modifications in the perception of self, perception of wholeness with the environment and spiritual experiences, which have great importante in the aforementioned groups of patients. Besides, it shows little to no side effects. This paper presents a review to reinforce the hypothesis of the therapeutic use of psilocybin in depression and anxiety in populations that can benefit the most of psychedelic therapy.
References
Aversi-Ferreira et al. (2013). Confrontation between ethnopharmacology and scientific results of the herbal medicaments from Brazil to be applied in primary health care. Journal of Medicinal Plants Research, 7(14), 845-856.
Barnby, J. M. & Mehta, M. A. (2018). Psilocybin and mental health-don't lose control. Front. Psychiatry, 3. DOI: https://doi.org/10.3389/fpsyt.2018.00293.
Bershad, A. K. et al. (2019). Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biological Psychiatry, 86(10), 792-800. DOI: https://doi.org/10.1016/j.biopsych.2019.05.019.
Bloch, S. et al. (2007). Psychological adjustment of men with prostate cancer: a review of the literature. Biopsychosoc Med, 1(2). DOI: https://doi.org/10.1186/1751-0759-1-2.
Bonn-Miller, M. O. et al. (2007). Associations between psychedelic use, abuse, and dependence and lifetime panic attack history in a representative sample. J Anxiety Disord, 21(5), 730-41. DOI: https://doi.org/10.1016/j.janxdis.2006.09.014.
Byock, I. (2018). Taking Psychedelics Seriously. Journal of Palliative medicine, 21(4). DOI: https://doi.org/10.1089/jpm.2017.0684.
Carhart-Harris, R. L., Bolstridge, M., Day & C. M. J. et al (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399-408. DOI: https://doi.org/10.1007/s00213-017-4771-x.
Carhart-Harris, R. L., Roseman, L. & Bolstridge, M. et al (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep, 7, 13187. DOI: https://doi.org/10.1038/s41598-017-13282-7.
Carhart-Harris, R. L. et al (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 7, 619-627. DOI: https://doi.org/10.1016/S2215-0366(16)30065-7.
Chang, V. et al (2007). Pain and palliative medicine. Journal of rehabilitation research and development, 44(2), 279-94. DOI: https://doi.org/10.1682/JRRD.2006.06.0067.
Chochinov, H. M. et al. (2009). The landscape of distress in the terminally ill. J Pain Symptom Manage, 38(5), 641-9. DOI: https://doi.org/10.1016/j.jpainsymman.2009.04.021.
Chochinov, H. M. et al. (2008). The patient dignity inventory: a novel way of measuring dignity-related distress in palliative care. J Pain Symptom Manage, 36(6), 559-71. DOI: https://doi.org/ 10.1016/j.jpainsymman.2007.12.018.
Costa et al (2018). The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders. Evidence-Based Complementary and Alternative Medicine. DOI: https://doi.org/10.1155/2018/7686913.
Cowen, P. (2016). Altered states: psilocybin for treatment-resistant depression. Lancet Psychiatry, 3(7), 592-3. DOI: https://doi.org/10.1016/S2215-0366(16)30087-6.
Dos Santos, R. G. et al (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology, 6(3), 193-213. doi: https://doi.org/10.1177/2045125316638008.
Dos Santos, R. G. et al (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety and substance use disorders: a systematic review of systematic reviews. Expert Review of Clinical Pharmacology, 11(9), 889-902. DOI: https://doi.org/10.1080/17512433.2018.1511424.
Dos Santos, R. G. & Hallak, J. E. C. (2019). Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neurosci Biobehav Rev, 108, 423-434. DOI: https://doi.org/10.1016/j.neubiorev.2019.12.001.
Erritzoe, D. et al. (2018). Effects of psilocybin therapy on personality structure. Acta Psychiatric Scand, 138(5), 368-378. DOI: https://doi.org/10.1111/acps.12904.
Erritzoe, D. et al. (2019). Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenges. Springer Nature – Neuropsychopharmacology, 45(5), 804-810. DOI: 10.1038/s41386-019-0567-5
Gandy, S. (2017). Dying to live: The power of transcendence in the treatment of existential anxiety. Journal of Interdisciplinary Consciousness Studies, 1(2), 25-36. Retrieved from http://www.tjics.org/index.php/TJICS/article/view/14.
Griffiths, R. R.; Richards, W. A. & Mccann, U. et al. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283. DOI: https://doi.org/10.1007/s00213-006-0457-5.
Griffiths, R. R. et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. DOI: https://doi.org/10.1177/0269881116675513.
Gripp, S. et. al. (2007). Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol, 25(22), 3313-3320. DOI: https://doi.org/10.1200/JCO.2006.10.5411.
Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 277, 99-120. DOI: https://doi.org/10.1016/j.bbr.2014.07.016.
Hebert, R. et al (2009). Preparing Family Caregivers for Death and Bereavement. Insights from Caregivers of Terminally III Patients. Journal Of Pain And Symptom Management, 37, 3-12. DOI: https://doi.org/10.1016/j.jpainsymman.2007.12.010.
Kelly, J. R. et al (2020). Psychedelic science in post-COVID-19 psychiatry. Irish Journal Of Psychological Medicine, 1–6. DOI: https://doi.org/10.1017/ipm.2020.94.
Kolva, E. et al. (2011). Anxiety in terminally ill cancer patients. J Pain Symptom Manage, 42(5), 691-701. DOI: https://doi.org/10.1016/j.jpainsymman.2011.01.013.
Kraehenmann, R. et al. (2015). Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biological Psychiatry, 78, 572-581. DOI: https://doi.org/10.1016/j.biopsych.2014.04.010.
Kraehenmann, R. et al. (2016). The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage: Clinical, 11, 53-60. DOI: https://doi.org/10.1016/j.nicl.2015.08.009.
Lim, C. H.; Kangas, B. & Bergman, J. (2018). The Utility of Psilocybin in Managing Anxiety and Depression in Cancer Patients. Journal of Young Investigators. DOI: https://doi.org/10.22186/jyi.35.2.45-49.
Ly, C. et al. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep, 23, 3170-82. DOI: https://doi.org/10.1016/j.celrep.2018.05.022.
McCorvy, J. D; Olsen, R. H. J. & Roth, B. L. (2016). Psilocybin for depression and anxiety associated with life-threatening illnesses. Journal of Psychopharmacology, 30(12), 1209-1210. DOI: https://doi.org DOI: http://dx.doi.org/10.1177/0269881116675771.
Mithoefer, M. C.; Grob, C. S & Brewerton, T. D. (2016). Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry, 3(5):481-8. DOI: http://dx.doi.org/10.1016/ S2215-0366(15)00576-3.
Nutt, D. (2016). Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of Psychopharmacology, 30(12), 1163-1164. DOI: https://doi.org/10.1177/0269881116675754.
Passie, T. et al. (2002). The pharmacology of psilocybin. Addiction Biology, 7(4), 357-364. DOI: https://doi.org/10.1080/1355621021000005937.
Phelps A.C. et al. (2009). Association between religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. Jama, 301(11), 1140-7. DOI: doi: https://doi.org/10.1001/jama.2009.341.
Preller, K. H. et al. (2017). The fabric of meaning and subjective effects in LSD- induced states depend on serotonin 2A receptor activation. Curr Biol, 27, 451–7. DOI: https://doi.org/ 10.1016/j.cub.2016.12.030.
Preller, K. H. et al. (2020). Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. Biological Psychiatry, 88(2), 197-207. DOI:https://doi.org/10.1016/j.biopsych.2019.12.027.
Roseman, L.; Nutt, D. J. & Carhart-harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol, 17. DOI: https://doi.org/10.3389/fphar.2017.00974.
Roseman et al. (2018). Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. 142, 263-269. DOI: https://doi.org/10.1016/j.neuropharm.2017.12.041.
Ross, S. (2018). Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. International Review of Psychiatry, 30(4), 317-330.DOI: https://doi.org/10.1080/09540261.2018.1482261.
Ross S, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol, 30(12), 1165-1180. DOI: https://doi.org/10.1177/0269881116675512.
Rubinstein, E. et al. (2015). A call to action: the global response to dementia through policy innovation. Dementia. 37p. Retrieved from https://www.wish.org.qa/wp-content/uploads/2018/01/WISH_Dementia_Forum_Report_08.01.15_WEB.pdf.
Rucker, J. J. H.; Iliff, J. & Nutt; D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 142:200-218. DOI: https://doi.org/ 10.1016/j.neuropharm.2017.12.040.
Salih, L. H; Kaushik, A. (2013). Mini Review on psychedelic drugs: illumination on the hidden aspects of mind. American Journal Of Phytomedicine And Clinical Therapeutics. 1(5), 432-444. Retrieved from https://www.imedpub.com/articles/mini-review-on-psychedelic-drugsillumination-on-the-hidden-aspects-of-mind.pdf.
Schmid, Y; Liechti M. E. (2018). Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. 235, 535-45. DOI: https://doi.org/10.1007/s00213-017-4733-3.
Singewald, N. et al. (2015). Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacology & Therapeutics, 149, 150-190. DOI: https://doi.org/10.1016/j.pharmthera.2014.12.004.
Sorger, B. et al. (2007). Decision-making capacity in elderly, terminally ill patients with cancer. Behavioral Sciences & The Law, 25, 393-404. DOI: https://doi.org/10.1002/bsl.764.
Tancer M. & Johanson C. E. (2003). Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend, 72(1), 33-44. DOI:http://doi.org/10.1016/s0376-8716(03)00172-8.
Tylš, F.; Páleníček, T. & Horáček, J. (2014). Psilocybin – Summary of knowledge and new perspectives. European Neuropsychopharmacology, 24, 342-356. DOI: https://doi.org/10.1016/j.euroneuro.2013.12.006.
Valentiner D. P., Mounts N. S. & Deacon B. J. (2004). Panic attacks, depression and anxiety symptoms, and substance use behaviors during late adolescence. J Anxiety Disord, 18(5), 573-85. Retrieved from http://bases.bireme.br/cgibin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&src=goo-gle&base=ADOLEC&lang=p&nextAction=lnk&exprSearch=15275940&indexSearch=ID.
Watts, R. et al. (2017). Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. Journal of Humanistic Psychology, 57(5), 1-45. DOI: https://doi.org/10.1177/0022167817709585.
Young K. S. et al. (2017). Treatment for social anxiety disorder alters functional connectivity in emotion regulation neural circuitry. Psychiatry Res Neuroimaging, 30(261), 44-51. DOI: https://doi.org/10.1016/j.pscychresns.2017.01.005.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Myla Chistie Araujo Custodio Bonifácio; Pietra Bruna Batrbosa Bento; Kaynara Trevisan; Renata Cristina Pereira; Micheli Patricia de Fátima Magri; Tales Alexandre Aversi-Ferreira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
